Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Russell (London, United Kingdom), A. Datta (London, United Kingdom), K. Newell (Surrey, United Kingdom), S. Jones (Lichfield, United Kingdom), J. Conway (London, United Kingdom), L. Saktkoo (New Orlean, United States of America), M. Wickremasinghe (London, United Kingdom). Development of a patient reported experience measure (PREM) for idiopathic pulmonary fibrosis (IPF). 1320

Member's Comments

No comment yet.

Related content which might interest you: Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients? Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR) Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 Treatment of idiopathic pulmonary fibrosis (IPF) with nintedanib: an experience from the compassionate use program (CUP) in Estonia Source: International Congress 2017 – Clinical problems in lung diseases Year: 2017 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Health status & impact of living with idiopathic pulmonary fibrosis (IPF): UK & Ireland Delphi survey Source: International Congress 2016 – IPF clinical Year: 2016 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study Source: Annual Congress 2006 - Quality of life in various respiratory diseases Year: 2006 Pulmonary tuberculosis (TB) as a complication of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Bosentan in idiopathic pulmonary fibrosis (IPF) patients: the BUILD 1 study Source: Eur Respir J 2006; 28: Suppl. 50, 383s Year: 2006 Quality of life of patients with idiopathic pulmonary fibrosis (IPF) - What can the Australian IPF registry tell us? Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions Year: 2010 Central European idiopathic pulmonary fibrosis (IPF) patients survey Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019